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Abstract 
Background: Poor nebuliser hygiene can result in bacterial contamination and 
risk of infections. The aim of this study was to assess the prevalence of fungal 
contamination of nebulisers used by adults with cystic fibrosis.  
Methods: 170 nebulisers from 149 subjects were screened by wetting a sterile 
cotton swab with sterile water and swabbing each drug chamber. The swab 
was then plated out on Sabouraud and on Scel+ agar and incubated at 27oC 
for up to two weeks. 
Results: Fungal cultures were positive in 86 (57.7%) patient's devices. In 
28/149 (18.8%), 39/149 (26.2%), 47/149 (31.5%) and 20/149 (13.4%) of 
subjects Aspergillus species, yeasts, moulds and both yeasts and moulds 
were isolated respectively. There was no difference in contamination rates 
between different devices.  
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Conclusion: Nebuliser devices are frequently contaminated by moulds and 
yeasts and emphasis should be placed on ensuring adequate nebuliser 
hygiene. 
 
Keywords 
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Introduction  
Nebulised drugs including antibiotics and mucolytics, remain essential in the 
management of cystic fibrosis (CF). Their introduction has been instrumental 
in improving clinical stability and life expectancy. Nebulisation of antibiotics 
has the added advantage of delivering very high drug concentrations directly 
to the site of infection while minimising side effects such as nephrotoxicity and 
ototoxicity.  
 
Multiple drug regimens are often required to attain optimal outcome. This 
dependence on time consuming regimens increases treatment burden and 
often impacts on adherence. The introduction of devices such as the e Flow® 
and iNeb® have helped to reduce some of this burden by improved portability, 
usability and speed of administration(1). Despite these changes adherence to 
treatment and nebuliser hygiene can remain low(2, 3).  
 
Previous studies have demonstrated a relationship between nebuliser hygiene 
and the risk of bacterial infections(4-7). Despite the high prevalence of fungal 
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colonisation and infection in patients with CF, the role of nebuliser devices as 
a potential source of primary inoculum and re-infection has not been 
investigated. Aspergillus fumigatus remains the most common fungal species 
to affect patients with CF and can be isolated in up to 58% of sputum 
samples. The fungus results in a spectrum of conditions ranging from 
hypersensitivity to frank infection(8). These include bronchopulmonary 
aspergillosis (ABPA), aspergillus bronchitis, aspergilloma and in post 
transplant recipents, invasive aspergillosis.  Other fungi such as 
Scedosporium apiospermum have also been implicated in pulmonary 
exacerbation.  
 
The aim of this study was to analyse the fungal flora of nebuliser devices from 
people with CF and to compare contamination rates between the various 
devices. 
 
Materials and Methods 
 
Subjects 
Adult attending the Leeds CF Unit at St James University Hospital were 
prospectively recruited. All patients had classical features of cystic fibrosis in 
conjunction with either two mutations or two abnormal sweat tests. Following 
recruitment, subjects were requested to bring their nebuliser devices to their 
next outpatient appointment. No further information was provided and 
cleaning was not mentioned. The study was approved by the North Leeds 
Ethics Committee (11/YH/0296).  
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Device sampling  
Samples were obtained from the equipment by wetting a sterile cotton swab 
with sterile water and swabbing each drug chamber. INeb horns were 
swabbed separately. Some individuals with INebs had multiple chambers. 
Samples as well as negative controls were sent to the  Mycology Laboratory 
at Leeds General Infirmary. 
 
Laboratory investigations  
Swabs were plated out on Sabouraud agar and on Scel+ agar to select for 
Scedosporium sp(9). All plates were incubated at 27oC for up to two weeks. 
Any mould or yeast growing on the plate was identified immediately or stored 
at ±80oC prior to being recovered and identified at a later date. Yeasts were 
initially identified by germ tube test. All germ tube negative isolates were 
identified by MALDI-TOF examination using the Bruker Biotyper system(10) or 
where this was not successful, the Biomerieux API32C yeast identification 
method. Moulds were identified by microscopic examination, or if this was not 
sufficient, by sequencing of the ITS1, 5.8S and ITS2 region and comparing 
the sequence with the Genbank database by BLAST search(11). Sputa were 
treated with an equal volume of 0.1% dithiothreitol and a 10ul loopful 
inoculated onto 3 Sabourauds agar plates which were incubated for 7 days at 
28, 35 and 45qC. All moulds are routinely examined though not always 
identified to species level. 
 
Analysis 
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The proportion of devices with any fungal contamination were analysed 
according to device using significance tests and assuming a normal 
distribution. Device cultures were compared with the previous 6 months of 
sputum cultures 
 
Results 
A total of 170 nebulisers, some with multiple chambers were sampled, 
representing a mean of 1.87 and median of 2 (range 1-4) devices from 149 
subjects.  
 
Overall, 86/149 (57.7%) of subjects had positive fungal cultures from at least 
one of their devices, with 39/149 (26.2%) being yeasts, 47/149 (31.5%) 
moulds and 20/149 (13.4%) a combination of yeasts and moulds.  
 
There was no significant difference in the contamination rates of iNeb and 
Eflow devices (p >0.05) (Table 1). While the contamination rate of 
Ventstreams appeared lower, numbers of devices used were small. Similar 
rates of fungal contamination were seen for  iNeb chambers and horns. There 
was no correlation between medication administered and rate of 
contamination (Table 2).  
 
Aspergillus fumigatus  was the most frequent mould isolated (Table 3) 
followed by  Penicillium sp.  P. commune was the most common identifiable 
species from this genus. A number of Lecanicillium sp.isolates were also 
identified. Exophiala sp, were isolated from, five devices. One was identified 
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as E. oliosperma, one as E. jeanselmei and three as Exophiala sp., None 
were E. dermatiditis. Thus a total of 4/149 (2.7%) of all study subjects had one 
or more devices contaminated with Exophiala sp.  
 
The most frequent yeast to contaminate devices was Candida guilliermondii 
followed by C. parapsilosis. Contamination with environmental 
basidiomycetous yeasts in the genera Rhodotorula and Cryptococcus (but not 
Cr. neoformans) was also common. The commonest cause of oral 
colonisation and infection, C. albicans was isolated on a single occasion.  
 
When the results of culture from devices was compared with sputum culture 
from the previous six months, no obvious correlation was seen between 
positive culture from devices and previous sputum specimens (p >0.05). Most 
people with CF who were sputum culture positive for A. fumigatus (46/50) did 
not have devices contaminated with this fungus.  Of the six study subjects 
with Exophiala sp. or black yeasts isolated from devices, none had Exophiala 
sp. isolated from sputum culture in the previous six months.  Of seven study 
subjects who had black yeasts isolated from sputum culture in the previous 6 
months (provisionally identified as Exophiala sp.), none had Exophiala 
isolated from devices. No Scedosporium sp. were isolated from any device.  
All controls samples were negative.  
 
 
Discussion 
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Although there is an increasing body of evidence supporting a relationship 
between nebuliser hygiene and the risk of bacterial infections(4, 5), there is a 
paucity of data on fungal contamination.  A recent one day study by Jadhay et 
demonstrated a high prevalence of fungal colonization of oxygen humidifier 
and Hudson's nebuliser chambers in ICUs, wards, the casualty and OPD(6). 
Significantly, 15% of devices remained colonised despite disinfection with 
70% alcohol.  
 
The present study has shown a high prevalence of contaminated nebuliser 
devices used by patients with CF. Over 57% of subjects had positive fungal 
cultures in at least one device including yeasts, moulds or a combination of 
both.  There appears to be no significant difference between the rates of 
contamination between the various devices. We were surprised by the 
similarity in the  contamination rate of conventional nebulisers and those with  
mesh technology. We had expected to find an increase rate of contamination 
in the conventional devices and had not expected to isolate fungus from the 
horn of the ineb.  While contamination of Ventstreams appeared low, numbers 
were too small for the results to be meaningful.  
 
We routinely instruct patients on how to follow the manufacturer's guidelines 
for cleaning the various devices. It is likely that such protocols are only 
partially adhered to and that following initial contamination, further cleaning 
becomes less effective due to the presence of polymicrobial biofilms. 
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There was no apparent correlation between fungal contamination of nebuliser 
devices and previous sputum mycology. Whilst these results do not exclude 
the role of the nebuliser device as a potential reservoir for pathogenic fungi 
much more in depth longitudinal studies are needed.   
 
Aspergillus fumigatus was the most frequent mould isolated followed by 
Penicillium sp with yeasts being found on many devices. While yeasts are 
regularly isolated from sputum specimens of people with CF, yeasts are not 
generally thought to represent a major clinical problem(12). It was notable that 
the distribution of yeasts isolated from nebuliser devices did not correlate with 
yeasts that normally colonies or infect the oral cavity. For example Candida 
albicans is a common isolate from CF sputum and assumed to represent oral 
flora but only one device was contaminated with this species. The yeasts 
contaminating the nebuliser devices were often those associated with the 
formation of biofilms such as C. parapsilosis. Specimens also included  
environmental yeasts such as Rhodotorula sp, which are infrequently isolated 
from clinical specimens due to their inability to grow well at 37C.  
 
In clinical practice we have recognised significant differences in patient 
adherence to cleaning regimens with some nebuliser and compressors being 
returned in a poor state of cleanliness.  Education and adherence with the 
manufacturers cleaning regimens can reduce contamination, highlighting the 
importance of regular cleaning and disinfection(13). Further research is 
needed to assess the relative effectiveness of different cleaning methods.  
There is presently no data on the rate of fungal contamination of the new dry 
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powder antibiotic inhalers although the risk of contamination is likely to be 
significantly lower in these disposable devices.   
 
In conclusion, fungal contamination of nebuliser devices used by patients with 
CF appears common and is not device-specific More emphasis needs to be 
placed on improving nebuliser hygiene through education and appropriate 
cleaning regimens.  
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Device No. No. positive % positive 
Ineb    
       Horn   94 31 33.0 
       Drug chamber 199 71 35.7 
       Total 293 102 34.8 
 
Eflow   48 21 43.7 
    
Sidestream   22 9 40.9 
    
Ventstream    6 1 16.7 
 
Total nebulisers 170 62 36.5 
 
Table 1: Fungal contamination rates for the iNeb, Eflow, Sidestream and Venstream 
nebulisers. 
 
 
 
Table 1
Medication Device No. No. positive % positive 
7% NaCl Ineb 
Eflow 
Sidestream 
Ventstream 
 
24 
5 
2 
1 
11 
2 
0 
0 
45.8 
40 
0 
0 
7% NaCl and ventolin 
 
Ventstream 1 1 100 
Promixin 
 
Ineb 57 19 33.3 
DNase Ineb 
Eflow 
Sidestream 
 
81 
24 
14 
33 
13 
7 
40.74 
54.17 
50.00 
Tobramycin Ineb 
Eflow 
Pari Ic 
Ventstream 
 
25 
10 
2 
1 
5 
5 
1 
0 
20.00 
50.00 
50.00 
0.00 
Aztreonam for Inhalation 
Solution  
 
Eflow 3 0 0 
Ventolin Ineb 
Eflow 
Sidestream 
Ventstream 
 
8 
6 
4 
1 
1 
1 
0 
0 
12.50 
16.67 
0.00 
0.00 
Ventolin and Atrovert Venstream 
Sidestream 
 
1 
1 
0 
1 
0 
100 
Bricanyl 
 
Sidestream 1 1 100 
Combivent 
 
Ineb 1 0 0 
Atrovent 
 
Ineb 1 1 100 
Taurolidine 
 
Ventstream 1 0 0 
 
 
Table 2:  Positive fungal isolates identified from different devices according 
medication type. 
 
 
Table 2
  Previously 
Reported 
from 
CF sputum 
Previously 
Reported 
from non-CF 
sputum 
Total no. 
of 
devices 
% of devices Total no. study 
participants with 
at least one 
contaminated  
device 
% of study  
participants 
Aspergillus fumigatus  + + 24 9 20 13 
Aspergillus niger  + + 3 1 3 2 
Aspergillus  versicolor  + + 1 <1 1 <1 
Cladosporium 
sphaerospermum 
+ + 1 <1 1 <1 
Exophiala 
oligosperumum 
  1 <1 1 <1 
Exophiala sp.  + + 3 1 2 1 
Exophiala jeanselmei  
  2 <1 1 <1 
Lecanicillium lecanii  
  5 2 3 2 
Lecanicillium sp. 
  2 <1 2 1 
Microsporum fulvum  
  1 <1 1 <1 
Myxotrichum sp. 
  1 <1 1 <1 
Penicillium commune  
  4 <1 4 3 
Penicillium glabrum  
  1 <1 1 <1 
Penicillium griseofulvin 
  1 <1 1 <1 
Penicillium coryphilum 
  1 <1 1 <1 
Penicillium digitatum  
 + 2 <1 2 1 
Penicillium sp. + + 10 4 5 3 
Rhizopus oryzae  
  1 <1 1 <1 
Scopulariopsis 
chartarum  
  1 <1 1 <1 
Ulocladium chartarum  
  2 <1 1 <1 
Aureobasidium 
pullulans  
 + 2 <1 1 <1 
Candida albicans  + + 1 <1 1 <1 
Candida guilliermondii  
 + 36 13 22 15 
Table 3
Candida holmii  
  1 <1 1 <1 
Candida krusei  
 + 2 <1 1 <1 
Candida lipolytica  
  1 <1 1 <1 
Candida parapsilosis  + + 29 11 20 13 
Candida pelliculosa  
  3 1 2 1 
Candida sake  
  1 <1 1 <1 
Candida sp.  + + 1 <1 1 <1 
Candida zeylanoides  
 + 1 <1 1 <1 
Cryptococcus sp. 
 + 1 <1 1 <1 
Cryptococcus albidus  
  4 1 3 2 
Cryptococcus 
unigutatulus 
  10 4 5 3 
Cryptococcus 
carnescens 
  1 <1 1 <1 
Rhodotorula glutinis  +  24 9 17 11 
Rhodotorula 
mucilaginosa  
+  21 8 17 11 
Rhodotorula minuta 
  5 2 4 3 
Rhodotorula sp. 
 + 1 <1 1 <1 
Sporobolomyces 
roseus  
  1 <1 1 <1 
Trichosporon asahii  
 + 1 <1 1 <1 
 
Table 3:  
+Previous reports of fungal isolates from CF and non CF sputum respectively. Number of devices with positive fungal 
isolates and number of study participant with at least one infected device.  
 
 
 
 
 
 
1 
 
Fungal contamination of nebuliser devices used by people with cystic fibrosis 
 
 
D Peckham1*, K Williams1, S. Wynne1, M. Denton2, K. Pollard1, R. Barton3  
 
/HHGV&HQWUHIRU&\VWLF)LEURVLV6W-DPHV¶V8QLYHUVLW\+RVSLWDO, Leeds, 
United Kingdom 
 
2. Department of Microbiology, Leeds General Infirmary, Leeds, United 
Kingdom 
 
3. Mycology Reference Centre, Leeds General Infirmary, Leeds, United 
Kingdom 
 
 
*Corresponding author 
Dr Daniel Peckham 
Beckett Street 
St James's University Hospitals, Leeds 
Leeds, West Yorkshire, 
LS9 7TF 
Tel 0113 20 67170 
 
 
Abstract 
Background: Poor nebuliser hygiene can result in bacterial contamination and 
risk of infections. The aim of this study was to assess the prevalence of fungal 
contamination of nebulisers used by adults with cystic fibrosis.  
Methods: 170 nebulisers from 149 subjects were screened by wetting a sterile 
cotton swab with sterile water and swabbing each drug chamber. The swab 
was then plated out on Sabouraud and on Scel+ agar and incubated at 27oC 
for up to two weeks. 
Results: Fungal cultures were positive in 86 (57.7%) patient's devices. In 
28/149 (18.8%), 39/149 (26.2%), 47/149 (31.5%) and 20/149 (13.4%) of 
subjects Aspergillus species, yeasts, moulds and both yeasts and moulds 
were isolated respectively. There was no difference in contamination rates 
between different devices.  
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Conclusion: Nebuliser devices are frequently contaminated by moulds and 
yeasts and emphasis should be placed on ensuring adequate nebuliser 
hygiene. 
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Introduction  
Nebulised drugs including antibiotics and mucolytics, remain essential in the 
management of cystic fibrosis (CF). Their introduction has been instrumental 
in improving clinical stability and life expectancy. Nebulisation of antibiotics 
has the added advantage of delivering very high drug concentrations directly 
to the site of infection while minimising side effects such as nephrotoxicity and 
ototoxicity.  
 
Multiple drug regimens are often required to attain optimal outcome. This 
dependence on time consuming regimens increases treatment burden and 
often impacts on adherence. The introduction of devices such as the e Flow® 
and iNeb® have helped to reduce some of this burden by improved portability, 
usability and speed of administration(1). Despite these changes adherence to 
treatment and nebuliser hygiene can remain low(2, 3).  
 
Previous studies have demonstrated a relationship between nebuliser hygiene 
and the risk of bacterial infections(4-7). Despite the high prevalence of fungal 
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colonisation and infection in patients with CF, the role of nebuliser devices as 
a potential source of primary inoculum and re-infection has not been 
investigated. Aspergillus fumigatus remains the most common fungal species 
to affect patients with CF and can be isolated in up to 58% of sputum 
samples. The fungus results in a spectrum of conditions ranging from 
hypersensitivity to frank infection(8). These include bronchopulmonary 
aspergillosis (ABPA), aspergillus bronchitis, aspergilloma and in post 
transplant recipents, invasive aspergillosis.  Other fungi such as 
Scedosporium apiospermum have also been implicated in pulmonary 
exacerbation.  
 
The aim of this study was to analyse the fungal flora of nebuliser devices from 
people with CF and to compare contamination rates between the various 
devices. 
 
Materials and Methods 
 
Subjects 
Adult attending the Leeds CF Unit at St James University Hospital were 
prospectively recruited. All patients had classical features of cystic fibrosis in 
conjunction with either two mutations or two abnormal sweat tests. Following 
recruitment, subjects were requested to bring their nebuliser devices to their 
next outpatient appointment. No further information was provided and 
cleaning was not mentioned. The study was approved by the North Leeds 
Ethics Committee (11/YH/0296).  
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Device sampling  
Samples were obtained from the equipment by wetting a sterile cotton swab 
with sterile water and swabbing each drug chamber. INeb horns were 
swabbed separately. Some individuals with INebs had multiple chambers. 
Samples as well as negative controls were sent to the  Mycology Laboratory 
at Leeds General Infirmary. 
 
Laboratory investigations  
Swabs were plated out on Sabouraud agar and on Scel+ agar to select for 
Scedosporium sp(9). All plates were incubated at 27oC for up to two weeks. 
Any mould or yeast growing on the plate was identified immediately or stored 
at ±80oC prior to being recovered and identified at a later date. Yeasts were 
initially identified by germ tube test. All germ tube negative isolates were 
identified by MALDI-TOF examination using the Bruker Biotyper system(10) or 
where this was not successful, the Biomerieux API32C yeast identification 
method. Moulds were identified by microscopic examination, or if this was not 
sufficient, by sequencing of the ITS1, 5.8S and ITS2 region and comparing 
the sequence with the Genbank database by BLAST search(11). Sputa were 
treated with an equal volume of 0.1% dithiothreitol and a 10ul loopful 
inoculated onto 3 Sabourauds agar plates which were incubated for 7 days at 
28, 35 and 45qC. All moulds are routinely examined though not always 
identified to species level. 
 
Analysis 
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The proportion of devices with any fungal contamination were analysed 
according to device using significance tests and assuming a normal 
distribution. Device cultures were compared with the previous 6 months of 
sputum cultures 
 
Results 
A total of 170 nebulisers, some with multiple chambers were sampled, 
representing a mean of 1.87 and median of 2 (range 1-4) devices from 149 
subjects.  
 
Overall, 86/149 (57.7%) of subjects had positive fungal cultures from at least 
one of their devices, with 39/149 (26.2%) being yeasts, 47/149 (31.5%) 
moulds and 20/149 (13.4%) a combination of yeasts and moulds.  
 
There was no significant difference in the contamination rates of iNeb and 
Eflow devices (p >0.05) (Table 1). While the contamination rate of 
Ventstreams appeared lower, numbers of devices used were small. Similar 
rates of fungal contamination were seen for  iNeb chambers and horns. There 
was no correlation between medication administered and rate of 
contamination (Table 2).  
 
Aspergillus fumigatus  was the most frequent mould isolated (Table 3) 
followed by  Penicillium sp.  P. commune was the most common identifiable 
species from this genus. A number of Lecanicillium sp.isolates were also 
identified. Exophiala sp, were isolated from, five devices. One was identified 
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as E. oliosperma, one as E. jeanselmei and three as Exophiala sp., None 
were E. dermatiditis. Thus a total of 4/149 (2.7%) of all study subjects had one 
or more devices contaminated with Exophiala sp.  
 
The most frequent yeast to contaminate devices was Candida guilliermondii 
followed by C. parapsilosis. Contamination with environmental 
basidiomycetous yeasts in the genera Rhodotorula and Cryptococcus (but not 
Cr. neoformans) was also common. The commonest cause of oral 
colonisation and infection, C. albicans was isolated on a single occasion.  
 
When the results of culture from devices was compared with sputum culture 
from the previous six months, no obvious correlation was seen between 
positive culture from devices and previous sputum specimens (p >0.05). Most 
people with CF who were sputum culture positive for A. fumigatus (46/50) did 
not have devices contaminated with this fungus.  Of the six study subjects 
with Exophiala sp. or black yeasts isolated from devices, none had Exophiala 
sp. isolated from sputum culture in the previous six months.  Of seven study 
subjects who had black yeasts isolated from sputum culture in the previous 6 
months (provisionally identified as Exophiala sp.), none had Exophiala 
isolated from devices. No Scedosporium sp. were isolated from any device.  
All controls samples were negative.  
 
 
Discussion 
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Although there is an increasing body of evidence supporting a relationship 
between nebuliser hygiene and the risk of bacterial infections(4, 5), there is a 
paucity of data on fungal contamination.  A recent one day study by Jadhay et 
demonstrated a high prevalence of fungal colonization of oxygen humidifier 
and Hudson's nebuliser chambers in ICUs, wards, the casualty and OPD(6). 
Significantly, 15% of devices remained colonised despite disinfection with 
70% alcohol.  
 
The present study has shown a high prevalence of contaminated nebuliser 
devices used by patients with CF. Over 57% of subjects had positive fungal 
cultures in at least one device including yeasts, moulds or a combination of 
both.  There appears to be no significant difference between the rates of 
contamination between the various devices. We were surprised by the 
similarity in the  contamination rate of conventional nebulisers and those with  
mesh technology. We had expected to find an increase rate of contamination 
in the conventional devices and had not expected to isolate fungus from the 
horn of the ineb.  While contamination of Ventstreams appeared low, numbers 
were too small for the results to be meaningful.  
 
We routinely instruct patients on how to follow the manufacturer's guidelines 
for cleaning the various devices. It is likely that such protocols are only 
partially adhered to and that following initial contamination, further cleaning 
becomes less effective due to the presence of polymicrobial biofilms. 
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There was no apparent correlation between fungal contamination of nebuliser 
devices and previous sputum mycology. Whilst these results do not exclude 
the role of the nebuliser device as a potential reservoir for pathogenic fungi 
much more in depth longitudinal studies are needed.   
 
Aspergillus fumigatus was the most frequent mould isolated followed by 
Penicillium sp with yeasts being found on many devices. While yeasts are 
regularly isolated from sputum specimens of people with CF, yeasts are not 
generally thought to represent a major clinical problem(12). It was notable that 
the distribution of yeasts isolated from nebuliser devices did not correlate with 
yeasts that normally colonies or infect the oral cavity. For example Candida 
albicans is a common isolate from CF sputum and assumed to represent oral 
flora but only one device was contaminated with this species. The yeasts 
contaminating the nebuliser devices were often those associated with the 
formation of biofilms such as C. parapsilosis. Specimens also included  
environmental yeasts such as Rhodotorula sp, which are infrequently isolated 
from clinical specimens due to their inability to grow well at 37C.  
 
In clinical practice we have recognised significant differences in patient 
adherence to cleaning regimens with some nebuliser and compressors being 
returned in a poor state of cleanliness.  Education and adherence with the 
manufacturers cleaning regimens can reduce contamination, highlighting the 
importance of regular cleaning and disinfection(13). Further research is 
needed to assess the relative effectiveness of different cleaning methods.  
There is presently no data on the rate of fungal contamination of the new dry 
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powder antibiotic inhalers although the risk of contamination is likely to be 
significantly lower in these disposable devices.   
 
In conclusion, fungal contamination of nebuliser devices used by patients with 
CF appears common and is not device-specific More emphasis needs to be 
placed on improving nebuliser hygiene through education and appropriate 
cleaning regimens.  
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